Opinion
Video
Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Science at AACR Aims to Overcome Cancer Care Barriers
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
Overweight-to-Obese Trajectory in Adulthood May Raise Ovarian Cancer Risk
5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas